Developing cGMP analog drug products - Mireca Medicines GmbH, Tübingen, is an expanding, preclinical stage company pioneering the development of proprietary cyclic guanosine monophosphate (cGMP)-analogs and drug delivery technologies to treat diseases caused by a dysregulation of cGMP, affecting protein kinase G (PKG). Mireca’s lead program focusses on the inhibition of cGMP signaling for neuroprotection and has obtained positive preclinical data for inherited retinal diseases (IRD) like Retinitis Pigmentosa (RP), Leber’s Congenital Amaurosis, and Stargardt’s disease.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Paul-Ehrlich Straße 5, Tübingen,baden-Württemberg 72076,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://mireca.eu
- Keywords
- Retina, retinitis pigmentosa, ocular drug delivery, targeted drug delivery, retinal degeneration, Leber´s congenital amaurosis.
- HQ
- Tübingen, Baden-Württemberg
Mireca Medicines Gmbh Questions
Mireca Medicines Gmbh's website is http://mireca.eu
Mireca Medicines Gmbh's LinkedIn profile is https://de.linkedin.com/company/mireca
Mireca Medicines Gmbh has
5 employees.
View email and phone details for 5
employees at Mireca Medicines Gmbh.
Mireca Medicines Gmbh's industry is
Biotechnology Research
Mireca Medicines Gmbh's top competitors are
2-Bbb Medicines Bv,
Oncolize,
Pharming Group,
Biotactical,
Eyesiu Medicines Bv,
Organon,
20med Therapeutics,
Biotech Booster,
Amarna Therapeutics,
Rapidemic.
Mireca Medicines Gmbh's categories are Biotechnology Research
Mireca Medicines Gmbh's founding year is 2017
